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1. Introduction 
A 7-valent pneumococcal conjugate vaccine using a non-toxic mutant of diphtheria toxin as a carrier protein 
(PCV7-CRM197) was licensed in 2000 in the US, and in 2001 in Canada.  Four doses (3+1) are recommended for 
routine immunization of children. In the provinces of Quebec and British Columbia, only 3 doses (2+1) are 
recommended for low-risk children. 
New vaccines are in development, including a 13-valent extension of PCV7-CRM197 (PCV13-CRM197). Another 
approach for polysaccharide conjugation is to use as a carrier a highly conserved surface lipoprotein found in almost 
all Haemophilus influenzae strains. An 11-valent vaccine (PCV11-HiD) was tested in a clinical trial, and a 10-valent 
product (PCV10-HiD) is expected to be marketed in the near future.
Economic analyses are increasingly important in decision making regarding new vaccines, and simulation models 
have to include indirect effects associated with polysaccharide-protein conjugate vaccine use. 
2. Objectives 
To develop a user-friendly and transparent simulation model allowing the comparison of the impact of different 
pneumococcal conjugate vaccines, using different immunization schedules in different epidemiological and 
economic situations. 
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Results of the base-case model for the province of Quebec are presented, comparing cost-effectiveness indices 
associated with the implementation of a 4-dose PCV7-CRM197 or a 4-dose PCV10-HiD program for children.   
3. Methods 
A ‘steady-state population’ instead of a traditional ‘cohort’ model was developed, and the two approaches are 
compared in Figure 1. 
The static and deterministic compartmental model included mutually exclusive outcomes shown in Figure 2. 
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Three scenarios were considered: no vaccine (pre PCV7-CRM197 situation; 3+1 scheduled administration of 
PCV7-CRM197; 3+1 scheduled administration of PCV10-HiD.
The demographic structure (Quebec population 2006) included 136 age-categories (single-month categories up to 
age 23 months and single-year categories from age 2 years up to 106 years). 
Canadian base-line incidence rates of selected outcomes (2001) and disease unit costs (Can$ 2001) were 
estimated in a previous study (Morrow et al. 2007), and utility values were defined in a study in the UK (Melegaro 
et al. 2004).  The distribution of Streptococcus pneumoniae (Sp) serotypes among invasive pneumococcal disease 
(IPD) cases were obtained from the Quebec provincial reference laboratory (Boulianne et al. 2007), and the 
distribution of otopathogens in the control group in the FinOM trial was selected as the best proxy (Eskola et al. 
2001).
Immunization program costs were estimated using a $71 per dose purchase price for the two vaccines (Quebec 
Ministry of Health, written communication).  Vaccination coverage in the target population was determined on the 
basis of results of the 2007 National Survey on Immunization in the US (CDC, unpublished data).   
For PCV7-CRM197, age-specific, dose-specific, and (for IPD and AOM) serotype-specific efficacy rates were 
estimated from randomized clinical trials and the ABC-CDC case-control study (Black et al. 2000; Eskola et al. 
2001; Black et al. 2002; Fireman et al. 2003; Palmu et al. 2004; Whitney et al. 2006).  Cross protection against 
serotypes belonging to the serogroups included in PCV7-CRM197 was considered.  For PCV10-HiD, protection 
against IPD was estimated from the ratio PCV10-HiD:PCV7-CRM197 in the proportion of responders with OPA 
titers  8 in immunogenicity trials (Hausdorff, written communication).   
For all-cause hospitalized pneumonia, PCV10-HiD efficacy (29.0%) was determined by experts, as compared 
with 20.5% for PCV7-CRM197 as observed for radiologically-confirmed pneumonia in clinical trial (Black et al. 
2002).  For ambulatory-treated pneumonia, protection rate (4.3%) was determined by experts on the basis of results 
for all-cause pneumonia in clinical trial (Black et al. 2002).   
For AOM and myringotomy with ventilation tube insertion (MVTI), PCV7-CRM197 efficacy was determined 
from results of the FinOM study assuming no replacement (Eskola et al. 2001).  PCV10-HiD efficacy was 
determined on the basis of results in the POET study (Prymula et al. 2006).   
For all outcomes, waning of immunity between age 3 years and 9 years was estimated by experts. 
In the base-case model, indirect effects were considered for IPD but not for pneumonia and AOM.  For the two 
vaccines, estimation of the combined effect of herd protection and bacterial replacement on IPD was based on 
ABC/CDC surveillance data showing 30% reduction in IPD incidence in persons aged 18 years and more, and 76% 
reduction in children < 5 years following PCV7-CRM197 implementation in the US (ABC-CDC online).   
Program costs and outcomes observed in the one-year reference period were not discounted.  Long-term financial 
and health losses associated with outcomes occurring in the one-year reference period were discounted at 3% per 
annum. 
4. Results 
Table 1 : Impact of programs 
 No vaccine PCV7-CRM197 PCV10-HiD
Residual burden of disease       
All cases  412 328 377 080 350 926 
IPD cases  1 021 603 603 
Pneumonia cases 52 168 51 257 51 062 
AOm cases 359 138 325 220 299 261 
MVTI cases 14 410 10 628 7 733 
Deaths  4 138 4 088 4 086 
Survivors with sequelae 13 8 8 
Life-years lost (discounted) 40 719 39 857 39 796 
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QALYs (discounted) 41 094 38 257 38 037 
        
Associated costs       
Direct program costs to health system $0 $17 698 304 $17 698 304 
Direct program costs to families $0 $434 048 $434 048 
Direct program costs to society $0 $18 132 352 $18 132 352 
Direct disease costs to health system $176 613 262 $167 387 742 $163 240 618 
Direct disease costs to families $33 205 852 $30 837 950 $29 291 250 
Direct disease costs to society $209 819 114 $198 225 692 $192 531 867 
Total direct costs to health system (program + disease) $176 613 262 $185 086 046 $180 938 921 
Total direct costs to families  
(program + disease) $33 205 852 $31 271 998 $29 725 298 
Total indirect costs $410 875 381 $388 601 281 $381 342 471 
Total costs to society
(direct + indirect) $620 694 495 $604 959 324 $592 006 691 
Table 2 : Cost-Effectiveness indices 
PCV7-CRM197 vs 
No vaccine 
PCV10-HiD
vs
No vaccine 
PCV10-HiD
vs
PCV7-CRM197
Marginal effects       
ǻ Total cases -35 248 -61 402 -26 154 
ǻ Cases of IPD -418 -418 1
ǻ Cases of pneumonia -912 -1 107 -195 
ǻ Cases of acute otitis media -33 918 -59 877 -25 959 
ǻ Deaths -50 -52 -2 
ǻ Survivors with sequelae -6 -6 1
ǻ Life-years lost (discounted) -863 -924 -61 
ǻ QALYs -2 838 -3 057 -219 
Marginal costs       
ǻ Total direct costs to health system (diseases+program) $8 472 784 $4 325 660 -$4 147 125 
ǻ Total direct cost to families (diseases+program) -$1 933 854 -$3 480 554 -$1 546 700 
ǻ Total indirect costs (diseases) -$22 274 101 -$29 532 910 -$7 258 809 
ǻ Total costs to society (direct + indirect) -$15 735 171 -$28 687 804 -$12 952 634 
        
Health care perspective      
$/Total cases $240 $70 PCV10-HiD
$/Cases of IPD $20 274 $10 351 dominant 
$/Cases of pneumonia $9 293 $3 908  
$/Cases of acute otitis media $250 $72  
$/Deaths $168 185 $82 665  
$/Life-years lost (discounted) $9 823 $4 682  
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$/QALYs (discounted0 $2 986 $1 415  
       
Societal perspective      
$/Total cases -$446 -$467 PCV10-HiD
$/Cases of IPD -$37 651 -$68 647 dominant 
$/Cases of pneumonia -$17 258 -$25 920  
$/Cases of acute otitis media -$464 -$479  
$/Deaths -$312 344 -$548 232  
$/Life-years lost (discounted) -$18 242 -$31 049  
$/QALYs (discounted) -$5 545 -$9 385  
5. Interpretation 
Implementation of a 4-dose PCV7-CRM197 program would have resulted in a substantial reduction in all 
outcomes. From a health care perspective, the program is not cost-saving but cost-effectiveness indices are very 
favourable.  From a societal perspective, the program is cost-saving.   
The use of PCV10-HiD instead of PCV7-CRM197 would have prevented substantially more AOM cases and 
associated costs.  The marginal benefit in terms of IPD prevention would have been low, and this is explained by the 
low incidence of invasive infections caused by the additional Sp serotypes included in PCV10-HiD (1, 5, and 7F) in 
the study population (Boulianne et al. 2007).  Both from a health care and societal perspective, PCV10-HiD would 
be the preferred option at equal purchase price. 
6. Limitations 
For PCV7-CRM197, efficacy data were mostly derived from pre-licensure clinical trials, and from post-marketing 
case-control and ecological studies.  PCV10-HiD, efficacy data were mostly derived from pre-licensure 
immunological studies and expert opinion.  This is a major limitation. 
In the model, baseline epidemiological data represented the situation existing before any use of PCV7-CRM197,
and the comparison between the two vaccines is valid for countries in which PCV7-CRM197 is not recommended yet 
or not frequently used.  For countries having a PCV7-CRM197 program, the comparison should start from data 
representing the current epidemiological situation.  The problem is to obtain valid information on the distribution of 
pathogens causing community-acquired pneumonia and otitis media.    
An important assumption in the model is the steady state. In the US, a steady state situation seems to have been 
reached both for the direct effect and herd protection associated with PCV7-CRM197 use, but this may not be the 
case for replacement. 
Results are based on scenarios assuming an equal purchase price for the two vaccines.  The pricing policy of 
vaccine manufacturers in a situation of competition is highly unpredictable. 
Only 4-dose schedules were considered in the model, and 3-dose schedules are now recommended in many 
countries.  Epidemiological studies under way in Quebec and the UK will provide the information needed for such 
analysis. Also, the model should also be extended to include scenarios with PCV13-CRM197.
Finally, conservative assumptions regarding indirect effects on community-acquired pneumonia and otitis media 
were included in the base-case scenario, and herd protection for these outcomes will be explored in future analyses. 
References
Morrow A. et al. Can J Infect Dis Med Microbiol 2007; 18: 121–127. 
Melegaro A. et al. Vaccine 2004; 22: 4203–14. 
Boulianne N. et al. Institut national de santé publique du Québec, 2007.
Eskola J. et al. N Engl J Med 2001; 344: 403–9. 
72  Philippe De Wals et al. / Procedia in Vaccinology 1 (2009) 67–72 
Black S et al. Pediatr Infect Dis J 2000; 19: 187–95. 
Fireman B. et al. Pediatr Infect Dis J  2003; 22: 10–16. 
Palmu A. et al. Pediatr Infect Dis J 2004; 23: 732–8. 
Whitney C. et al. Lancet 2006; 368: 1495–502. 
Prymula R. et al. Lancet 2006; 367: 740–8. 
Black S et al. Pediatr Infect Dis J 2002; 21: 810–5. 
Acknowledgements
The study was supported by an unrestricted grant from Glaxo-Smith-Kline. 
